Mammary Fibroblast-derived Hepatocyte Growth Factor Stimulates Growth and Morphogenesis of Mouse Mammary Tumor Cells in Primary Culture

Masato Sasaki, Masahiro Nishio, Yasukatsu Tsukada and Jumpei Enami

Research Laboratory, Zenyaku Kogyo Co., Ltd., 2-33-7 Oizumi, Nerima, Tokyo 178-0062

We have recently isolated a mammary growth factor from the conditioned medium of mouse mammary stromal fibroblasts and identified it as a mouse homologue of human HGF (hepatocyte growth factor). To elucidate the role of HGF in mouse mammary tumorigenesis, we produced recombinant mouse HGF and examined its effects on primary cultures of mouse mammary tumor cells in this study. HGF at concentrations above 20 ng/ml maximally stimulated the growth of mammary tumor cells in primary monolayer culture. HGF also stimulated the three-dimensional growth and branching morphogenesis of mammary tumor cells cultured inside collagen gels. A comparison of the growth-stimulating activity of HGF with that of EGF (epidermal growth factor) and KGF (keratinocyte growth factor) revealed that HGF is the most potent growth factor among the three. Immunological studies using an antibody against mouse HGF demonstrated that 74% of the growth-stimulating activity present in the mammary fibroblast-conditioned medium was abolished by the antibody, indicating that HGF is the major growth factor produced by the fibroblasts. These observations thus suggest a role for HGF as a mammary stromal fibroblast-derived factor which stimulates growth and morphogenesis of adjacent mammary tumor cells in vivo.

Key words: Hepatocyte growth factor — Mammary tumor — Mouse — Collagen gel

It has been frequently observed that epithelial tumor cells isolated from spontaneous mammary tumors of the mouse show only a limited growth potential when placed under in vitro conditions.1,2 Previously, we hypothesized that the failure of the tumor cells to grow in vitro might be the result of separation from the in vivo microenvironment surrounding them,3 since evidence suggested that mesenchymal- (or stromal-)epithelial interactions are important not only for embryonic organogenesis,4 but also for formation and regeneration of adult organs5 and for carcinogenesis.6,7 In an effort to reconstitute the microenvironment which supports the growth and branching morphogenesis of mammary tumor cells we found that mammary stromal fibroblasts produce a potent growth factor.2,6 We subsequently identified this factor as a mouse homologue of human hepatocyte growth factor (HGF) through purification, peptide sequencing and cDNA cloning.8

The active form of HGF, which consists of a heterodimer of α- and β-chains, was initially purified as a growth factor for primary cultures of liver parenchymal cells.9-12 The cDNA encoding human HGF was then cloned,13,14 and the c-met proto-oncogene product, c-Met, was identified as the receptor for HGF.15,16 HGF not only stimulates growth,17,18 but also promotes scattering,19,20 motility,21 branching morphogenesis of epithelial cells22 and invasion of cancer cell lines.23,24 Cytotoxic activity of HGF on certain tumor cells was also reported.25,26 Thus, HGF is now recognized as a multipotent stromal factor essential for various aspects of stromal- (or mesenchymal-) epithelial interactions.27,28

To elucidate the role of stromal HGF in mammary tumor growth we produced an active heterodimeric form of recombinant mouse HGF in this study and compared its potency with those of other growth factors. The effects of HGF on primary mammary tumor cells were evaluated using two different culture methods, i.e., monolayer culture on plastic and three-dimensional culture inside a collagen gel matrix.

**Materials and Methods**

**Animals** SHN mice kindly provided by Dr. H. Nagasawa, Faculty of Agriculture, Meiji University, and Dr. T. Mori, Zoological Institute, University of Tokyo, were maintained in our laboratory.

**Growth factors** EGF (epidermal growth factor, culture grade) was obtained from Becton Dickinson Labware (Bedford, MA). Recombinant human KGF (keratinocyte growth factor) was purchased from GIBCO BRL (Rockville, MD).

**Production and purification of recombinant mouse HGF** Mouse HGF cDNA cloned in pBluescript II KS vector (Stratagene, La Jolla, CA) was excised and reinserted into pBlueBac vector (Invitrogen, San Diego, CA) to yield pBlueBac/HGF. HGF-recombinant baculovirus was prepared using the “MAXBAC” baculovirus expression system (Invitrogen) according to the manufacturer’s instructions. Sf9 insect cells cultured in TNM-FH medium (Sigma, St. Louis, MO) were then infected with...
the HGF-recombinant virus. To obtain an active heterodimeric form of HGF, 10% fetal bovine serum (FBS, GIBCO BRL) was added to the culture medium. HGF was purified from the culture supernatant by a modification of the method of Shimizu et al. using S-Sepharose (Pharmacia LKB, Uppsala, Sweden) and heparin-Sepharose (Pharmacia LKB) with a linear gradient (0.3–1.5 M) of NaCl in 10 mM sodium phosphate buffer (pH 7.4) containing 0.1% CHAPS (3-[3-cholamidopropyl]dimethylammonio]-1-propane-sulfonate). The protein concentration of the HGF preparation was determined by quantification of amino acids after hydrolysis of HGF in a Waters Pico-Tag amino acid analysis system. A portion of the recombinant HGF preparation was analyzed by 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.

Immunization and preparation of IgG New Zealand white rabbits were immunized with recombinant mouse HGF (20 µg per rabbit) in complete Freund’s adjuvant (Difco, Detroit, MI) and boosted with the same amount of HGF in incomplete Freund’s adjuvant. Anti-HGF IgG was purified from the rabbit sera using HiTrap Protein G column (Pharmacia LKB). Preimmune serum obtained prior to immunization was similarly processed to obtain the control IgG.

Assay for growth-stimulating activity Mammary tumor cells were isolated as described previously. Briefly, spontaneous mammary tumors of SHN mice were successively digested with collagenase (Type I, Sigma) and actinase (Kaken Chem. Co., Tokyo), suspended in DME (Dulbecco’s modified Eagle’s medium; Nissui, Tokyo) supplemented with 10% FBS and 10% dimethylsulfoxide, and stored frozen in liquid nitrogen. For assay, frozen cells were thawed and plated at a density of 10⁵ cells per 16-mm well (Microplate, 24-wells; Iwaki Glass, Funabashi) and cultured in 1 ml of DME supplemented with 10% FBS. One day after the plating, various growth factors were added to the wells. DNA content was determined fluorometrically using diaminobenzoic acid (Tokyo Kasei, Tokyo) by the method of Hinegardner as described previously.

Assay for inhibition of growth-stimulating activity Conditioned medium was obtained from the 40th passage of mouse mammary fibroblasts cultured in DME supplemented with 5% calf serum (GIBCO BRL). Nine hundred microliters of DME supplemented with 5% calf serum containing either HGF (final concentration in the medium was 7 ng/ml) or EGF (final concentration in the medium was 21 ng/ml), or 900 µl of the above conditioned medium was preincubated either with anti-HGF IgG or with control IgG for 2 h at 37°C in a 5% CO₂/95% air incubator. The mixture was then added to each well of mammary tumor cells which contained 1 ml of DME supplemented with 10% FBS. DNA content was measured 3 days later.

Collagen gel matrix culture Collagen gels containing 10% FBS were prepared using a type I collagen solution from porcine tendon (Cellmatrix I-A; Nitta Gelatine, Osaka) as described previously. Tumor cells were embedded in collagen gels at a density of 10⁶ cells per 16-mm well, overlaid with DME supplemented with 10% FBS and growth factors, and cultured for 7 days. Medium change was done every other day. DNA content was measured after releasing the cells by collagenase treatment as described previously.

Statistical analysis Results are expressed as mean±SE from 3 or 4 wells. Student’s t test was used for statistical analysis.

RESULTS

Effect of HGF, EGF and KGF on growth of mammary tumor cells in primary monolayer culture To assess the role of mammary fibroblast-derived growth factor in mammary tumor growth, we first produced the active form of recombinant mouse HGF in a baculovirus expression system. HGF was detectable as a single band of approximately 80 kD under non-reducing conditions, whereas it migrated as two subunits consisting of an α-chain of 68 kD and β-chains of 33–35 kD (Fig. 1). The presence of two β-chains is consistent with the findings reported for human HGF, and may represent two differently glycosylated forms of the β-chain. Using this HGF we examined its growth-stimulating activity on mouse
mammary tumor cells in primary culture. Tumor cells dissociated from spontaneous mammary tumors of the SHN mouse attached to the substratum and formed a monolayer in a serum-supplemented medium (Fig. 2, A, B and C). In the absence of growth factor supplementation mitotic figures were rare and the tumor cells continued to spread and increase in size (Fig. 2D). When EGF was added to the culture medium, stimulation of growth was observed (Fig. 2E). However, the growth lasted only for a few days. Thereafter, the cells stopped dividing and tended to become enlarged. In contrast to EGF, HGF supported a sustained growth of mammary tumor cells (Fig. 2F). Frequent mitotic figures were present (arrows in Fig. 2F) until the cells reached confluence.

Dose-response curves of growth factors further confirmed the microscopic observations. Supplementation of either HGF or EGF stimulated a dose-dependent growth of mammary tumor cells (Fig. 3A). EGF at a concentration of 20 ng/ml stimulated a 1.9-fold increase in DNA/well over the control culture in 3 days, while the same concentration of HGF stimulated a 3.8-fold increase. On the other hand, KGF was ineffective in stimulating the growth even at high concentrations. Analysis of the time courses of growth revealed that both the growth rate and the saturation density of the HGF-treated cultures were higher than those of the EGF-treated cultures (Fig. 3B). Thus, mouse HGF proved to be a potent growth factor for mouse mammary tumor cells in primary monolayer culture.

Fig. 2. Photomicrographs of mouse mammary tumor cells in primary monolayer culture. Mammary tumor cells were cultured in DME supplemented with 10% FBS for 24 h (A, B, C). Then, 10 ng/ml of EGF (E) or 10 ng/ml of HGF (F) was added and the culture was continued for a further 68 h. Control culture (D) received no growth factor. A and D, B and E, C and F, are photomicrographs of the same colonies. The horizontal bar indicates 100 µm. Note the presence of mitotic figures in the HGF-treated culture (arrows in F).
Fig. 3. Effect of HGF, EGF and KGF on growth of mouse mammary tumor cells in primary monolayer culture. Mammary tumor cells were plated in 16-mm wells and cultured in DME supplemented with 10% FBS. (A) Dose-response curves. One day after the plating, various concentrations of HGF (●), EGF (○), or KGF (△) were added to the wells and the culture was continued for 3 days. The leftmost circle represents the DNA content one day after the plating. (B) Time courses of growth. One day after the plating, 20 ng/ml each of HGF (●) or EGF (○) was added to the experimental wells and the culture was continued for a maximum of 8 days. Control culture (△) received no growth factor. DNA content was measured as described in “Materials and Methods.” Data are expressed as mean±SE from 3 wells.

Fig. 4. Effect of anti-HGF IgG on growth-stimulating activities. (A) Inhibition of growth-stimulating activity of recombinant mouse HGF. Mammary tumor cells were cultured in the presence of 7 ng/ml of HGF and various concentrations of anti-HGF IgG (●), 7 ng/ml of HGF and 50 µg/ml of control IgG (○) or in the absence of HGF (△ and dotted line) for 3 days. DNA content was then measured. Data are expressed as mean±SE from 3 wells. (B) Inhibition of growth-stimulating activities of mammary fibroblast-conditioned medium (CM) and HGF. Mammary tumor cells were cultured in the presence of 7 ng/ml of HGF, 47% CM or 21 ng/ml of EGF together with anti-HGF IgG (solid columns, 25 µg/ml) or control IgG (open columns, 25 µg/ml) for 3 days. DNA content was then measured. “None” represents cultures maintained in the absence of growth factors or CM. Data are expressed as mean±SE from 4 wells. * P<0.001.
Effect of anti-HGF IgG on mammary growth-stimulating activity in the mammary fibroblast-conditioned medium

We next examined whether the major growth-stimulating activity present in the mammary fibroblast-conditioned medium is HGF. HGF at a concentration of 7 ng/ml stimulated a 3-fold increase in DNA/well of mammary tumor cells. This stimulatory effect of HGF was inhibited by simultaneous addition of anti-mouse HGF IgG in a dose-dependent manner (Fig. 4A). Control IgG at up to 50 µg/ml failed to inhibit the HGF-stimulated growth. Anti-mouse HGF IgG at a concentration of 25 µg/ml inhibited 96% of the growth-stimulating activity of 7 ng/ml of HGF, while it failed to inhibit the growth-stimulating activity of EGF, showing that the IgG specifically inhibited the growth-stimulating activity of HGF (Fig. 4B). The same concentration of anti-mouse HGF IgG inhibited 74% of the activity in the mammary fibroblast-conditioned medium. These results thus suggest that the major mammary tumor growth factor present in the mammary fibroblast-conditioned medium is HGF.

Effect of HGF on growth of mammary tumor cells cultured in collagen gels

Finally, we examined the effect of HGF on growth of mammary tumor cells cultured threedimensionally in a collagen gel matrix. As in monolayer culture, HGF stimulated the growth of mammary tumor cells in a dose-dependent manner in collagen gel culture (Fig. 5). EGF at a concentration of 20 ng/ml stimulated a 1.9-fold increase in DNA/well over the control culture in 7 days. The same concentration of HGF stimulated a 3-fold increase over the control culture. With regard to the effect of KGF, weak but definite stimulation of growth (a 1.4-fold increase in DNA/well over the control culture) was observed in collagen gels. This positive effect of KGF is in contrast to the absence of its effect in monolayer culture. Photomicrographs of outgrowths formed in collagen gels are shown in Fig. 6. Mammary tumor cells were inoculated as compact aggregates at plating (Fig. 6A). Cultivation in the absence of growth factors for 6 days resulted in the formation of a limited number of branches (Fig. 6B). Both EGF and HGF stimulated growth as well as branching morphogenesis of mammary tumor cells. EGF stimulated the formation of branches thicker than those formed in the HGF-treated culture (Fig. 6C). HGF increased the number of branches, but the branches were thinner than those found in EGF-treated cultures. Thus, outgrowths in the HGF-treated cultures assumed a rather fibroblastic appearance (Fig. 6D).

DISCUSSION

To elucidate the role of stromal fibroblast-derived HGF in growth of mouse mammary tumor cells in vivo, we used primary cultures in this study, since the tumor cells are less selected than the cells of established lines and therefore should reflect the in vivo characteristics more closely. Mammary tumor cells of the mouse usually lose their growth capacity soon after they are placed under in vitro monolayer culture conditions. We have previously hypothesized that the microenvironment surrounding the mammary tumor cells may strongly influence the growth of the tumor cells and it was found that mammary fibroblasts produce a potent factor which stimulates growth and branching morphogenesis of mammary epithelial cells. We subsequently identified this factor as mouse HGF. In this study we obtained an active form of recombinant mouse HGF and showed that HGF alone was sufficient to mimic the effect of mammary fibroblast-conditioned medium on growth and branching morphogenesis of mammary tumor cells in primary culture. We also showed that HGF constitutes the major growth-stimulating activity in the mammary-fibroblast-conditioned medium, i.e., it accounts for 74% of the total growth-stimulating activity, and that HGF is more potent than EGF or KGF under monolayer and collagen gel culture conditions. Although KGF was reported to be produced by adult human lung fibroblasts, and purified human KGF stimulates the proliferation of mouse mammary epithelial cells under serum-free conditions, it showed only a limited activity on mouse mammary tumor cells under the
serum-containing culture conditions employed in this study. As for EGF, a mammary growth-stimulating factor immunologically related to EGF has been reported to be present in the conditioned medium of fetal salivary mesenchymal cells. However, we assume that EGF is virtually absent in the conditioned medium of mammary fibroblasts used in this study, since activity which competes with the binding of $^{125}$I-labeled EGF to mammary tumor cells was undetectable in the mammary fibroblast-conditioned medium. It remains to be seen whether the conditioned medium contains other growth factor(s), since the anti-HGF IgG did not completely inhibit the growth-stimulating activity in the conditioned medium in this study.

Mouse mammary tumor cells in primary culture undergo branching morphogenesis in a three-dimensional collagen gel matrix. HGF has been reported to stimulate the branching morphogenesis of mammary epithelial cell lines cultured inside collagen gels. The branching morphogenesis of primary cultures of mammary epithelial cells is also stimulated by HGF as well as by mammary fibroblast-conditioned medium as shown in this study and in our previous studies. In addition, we have shown that HGF as well as mammary fibroblast-conditioned medium stimulated the formation of rather fibroblastic branches of mammary tumor cell outgrowths in contrast to the thick branches stimulated by EGF. The fibroblastic morphology of outgrowths has previously been reported for mammary tumor cells cultured inside collagen gels in the presence of 12-O-tetradecanoylphorbol 13-acetate (TPA), a protein kinase C-activating tumor promoter. TPA induced the disappearance of long actin microfila-

Fig. 6. Effect of HGF and EGF on branching morphogenesis of mouse mammary tumor cells cultured in collagen gels. Phase contrast photomicrographs were taken on the day of plating (A), after 6 days in culture in the absence of growth factors (B), in the presence of 20 ng/ml of EGF (C), or in the presence of 20 ng/ml of HGF (D). The horizontal bar indicates 100 µm.
Constitutive activation of Met by mutation in genomic mice, and this has resulted in induction of mammary tumors.62) We have examined the possibility of the presence of the HGF-Met autocrine loop in mammary tumorigenesis. Cell lines having artificially created HGF-Met autocrine loops showed increased tumor incidences in nude mice.58–60) The presence of such an autocrine loop has recently been identified in a mouse mammary tumor cell line, SP1.61) The evidence that the HGF transgenic mice developed a wide variety of tumors including mammary tumors as early as at the secondary passage level and human breast, lung and prostate fibroblasts in primary culture have been shown to produce HGF.2, 21, 54) HGF produced by the fibroblasts stimulates not only growth, but also scattering, motility and branching morphogenesis of a variety of normal epithelial cells and invasion of tumor cells.27) These pleiotropic effects of HGF are all transduced by the Met receptor tyrosine kinase55) expressed on various epithelial cells,16, 17) Thus, it is conceivable that alteration in the HGF-Met signaling pathway could participate in mammary tumorigenesis and metastasis. Constitutive activation of Met receptor tyrosine kinase by autophosphorylation has been reported in tpr-met transgenic mice, and this has resulted in induction of mammary tumors.56) Constitutive activation of Met by mutation of the c-met gene has also been reported.57) In addition to such Met activation, autocrine or paracrine production of HGF in the Met-positive cells could lead to tumorigenesis. Cell lines having artificially created HGF-Met autocrine loops showed increased tumor incidences in nude mice.58–60) The presence of such an autocrine loop has recently been identified in a mouse mammary tumor cell line, SP1.61) The evidence that the HGF transgenic mice developed a wide variety of tumors including mammary tumors further suggests the involvement of HGF/Met co-expression and an autocrine loop in mammary tumorigenesis.62) We have examined the possibility of the presence of an HGF-Met autocrine loop in spontaneous mouse mammary tumors. However, HGF was undetectable in the conditioned medium of the cultured tumor cells. Besides, the tumor cells always required the presence of HGF for sustained growth in vitro. Thus, the presence of an HGF-Met autocrine loop or constitutive Met activation has not yet been identified in spontaneous mammary tumors of the mice.

In addition to the possible active participation of HGF in mammary tumorigenesis, growth of pre-formed tumor cells could be stimulated by HGF produced by the stroma adjacent to the tumor. Expression of HGF mRNA in the virgin mouse and rat mammary gland has recently been reported from several laboratories.63–65) We have also confirmed the expression of HGF mRNA in the mouse mammary gland by northern blot analysis (Sasaki, M. and Enami, J., submitted for publication). Moreover, Yang et al.66) demonstrated by in situ hybridization that the stromal cells closely surrounding the ductal epithelial cells of the mammary gland express HGF mRNA. Studies led by Sakakura revealed that the fibroblastic mammary mesenchyme which surrounds the mammary rudiment,16, 66) when transplanted into the adult mammary gland, stimulated the branching morphogenesis of the duct system adjacent to the mesenchyme. In addition, the mesenchyme accelerated the appearance of mammary tumors in mammary tumor virus-carrying mice. Some of the tumors developed directly from the mammary gland adjacent to the transplanted mesenchyme.67) From these observations, Sakakura69) suggested that if any alteration occurs in the mammary stroma, such as a change to the embryonic state, the changed stroma would stimulate epithelial growth. A carcinogenic agent, if present at this time, would give rise to cancers with higher frequency. Although the chemical nature of the mediator of the embryonic stromal influence is currently not well understood, HGF derived from the mammary fibroblasts could be one of the candidates. The clarification of this awaits further investigation.

ACKNOWLEDGMENTS

We thank Mr. K. Hashimoto, President of Zenyaku Kogyo Co., Ltd., for continued support and encouragement throughout this study. We also thank Drs. H. Kobayashi and S. Kawashima of this Research Laboratory, and Drs. H. A. Bern and S. Nandi, University of California, Berkeley, for encouragement and critical discussions. This work was supported in part by a Grant-in-Aid for Cooperative Research from the Ministry of Education, Science, Sports and Culture of Japan.

(Received June 30, 1998/Revised August 7, 1998/Accepted August 26, 1998)

REFERENCES

1) Hosick, H. L. and Nandi, S.  Plating and maintenance of epithelial tumor cells in primary culture: interacting roles of serum and insulin. Exp. Cell Res., 84, 419–425 (1974).
2) Enami, J., Enami, S. and Koga, M.  Growth of normal and neoplastic mouse mammary epithelial cells in primary culture: stimulation by conditioned medium from mouse mammary fibroblasts. Gann, 74, 845–853 (1983).
3) Kratochvil, K.  Tissue interaction during embryonic development: general properties. In “Tissue Interactions in Carcinogenesis,” ed. D. Tarin, pp. 1–47 (1972). Academic
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*, **251**, 802–804 (1991).

17) Naldini, L., Weidner, K. M., Vigna, E., Narisimhan, R. P., Gaucino, G., Zarnegar, R., Michalopoulos, G. K. and Comoglio, P. M. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. *Oncogene*, **6**, 501–504 (1991).

18) Rubin, J. S., Chan, A. M.-L., Bottaro, D. P., Burgess, W. H., Taylor, W. G., Cech, A. C., Hirschfield, D. W., Wong, J., Miki, T., Finch, P. W. and Aaronson, S. A. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. *Proc. Natl. Acad. Sci. USA*, **88**, 415–419 (1991).

19) Gherardi, E., Gray, J., Stoker, M., Perryman, M. and Furlong, R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. *Proc. Natl. Acad. Sci. USA*, **86**, 5844–5848 (1989).

20) Weidner, K. M., Arakaki, N., Hartmann, G., Vanderkarkhove, J., Weingart, S., Rieder, H., Fonatsch, C., Tsubouchi, H., Hishida, T., Daikuhara, Y. and Birchmeier, W. Evidence for the identity of human scatter factor and human hepatocyte growth factor. *Proc. Natl. Acad. Sci. USA*, **88**, 7001–7005 (1991).

21) Stoker, M., Gherardi, E., Perryman, M. and Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. *Nature*, **327**, 239–242 (1987).

22) Montesano, R., Matsumoto, K., Nakamura, T. and Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. *Cell*, **67**, 901–908 (1991).

23) Weidner, K. M., Behrens, J., Vanderkarkhove, J. and Birchmeier, W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. *J. Cell Biol.*, **111**, 2097–2108 (1990).

24) Nakamura, T., Matsumoto, K., Kiiritsusho, A., Tano, Y. and Nakamura, T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. *Cancer Res.*, **57**, 3305–3313 (1997).

25) Hagishio, K., Shima, N., Goto, M., Itagaki, Y., Nagao, M., Yasuda, H. and Moriga, T. Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. *Biochem. Biophys. Res. Commun.*, **170**, 397–404 (1990).

26) Tajima, H., Matsumoto, K. and Nakamura, T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. *FEBS Lett.*, **291**, 229–232 (1991).

27) Matsumoto, K. and Nakamura, T. Emerging multipotent aspects of hepatocyte growth factor. *J. Biochem.*, **119**, 591–600 (1996).

28) Nagasawa, H., Yanai, R., Taniguchi, H., Tokuzen, R. and Nakahara, W. Two-way selection of a stock of Swiss albino mice for mammary tumorigenesis: establishment of two new strains (SHN and SLN). *J. Natl. Cancer Inst.*, **57**, 425–430 (1976).
29) Gak, E., Taylor, W. G., Chan, A. and Rubin, J. S.  Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. *FEBS Lett.*, **311**, 17–21 (1992).

30) Shimomura, T., Ochiai, M., Kondo, J. and Morimoto, Y.  A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to two chain form in serum-free culture. *Cytotechnology*, **8**, 219–229 (1992).

31) Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, Y., Morimoto, Y. and Kitamura, N.  Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. *J. Biol. Chem.*, **268**, 10024–10028 (1993).

32) Mizuno, K., Tanoue, Y., Okano, I., Harano, T., Kakada, K. and Nakamura, T.  Purification and characterization of hepatocyte growth factor (HGF)-converting enzyme: activation of pro-HGF. *Biochem. Biophys. Res. Commun.*, **198**, 1161–1169 (1994).

33) Shimizu, I., Ichihara, A. and Nakamura, T.  Hepatocyte growth factor in ascites from patients with cirrhosis. *J. Biochem.*, **109**, 14–18 (1991).

34) Laemmli, U.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, **230**, 680–685 (1970).

35) Enami, J., Yang, J. and Nandi, S.  Simultaneous production of casein and mammary tumor virus in mouse mammary epithelial cells grown on floating collagen gels. *Cancer Lett.*, **6**, 99–105 (1979).

36) Hinegardner, R. T.  An improved fluorometric assay for DNA. *Anal. Biochem.*, **39**, 197–201 (1971).

37) Enami, J. and Tsukada, Y.  Use of collagen gel as three-dimensional matrix for explant culture. In *“Cell & Tissue Culture: Laboratory Procedures,”* ed. J. B. Griffiths, A. Gak, E., Taylor, W. G., Chan, A. and Rubin, J. S.  Procession of casein and mammary tumor virus in mouse mammary epithelial cells. *Cytotechnology*, **8**, 219–229 (1992).

38) Enami, J. and Tsukada, Y.  Use of collagen gel as three-dimensional matrix for explant culture. In *“Cell & Tissue Culture: Laboratory Procedures,”* ed. J. B. Griffiths, A. Gak, E., Taylor, W. G., Chan, A. and Rubin, J. S.  Procession of casein and mammary tumor virus in mouse mammary epithelial cells. *Cytotechnology*, **8**, 219–229 (1992).

39) Kawamura, K.  Growth of an established line of mouse mammary tumor cells and mouse mammary epithelial cells in primary culture under serum-free conditions. Master’s thesis, Faculty of Agriculture, University of Tokyo (1983).

40) Panos, R. J., Rubin, J. S., Csaky, K. G., Aaronson, S. A. and Mason, R. J.  Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. *J. Clin. Invest.*, **92**, 969–977 (1993).

41) Imagawa, W., Cunha, G. R., Young, P. and Nandi, S.  Keratinocyte growth factor and acidic fibroblast growth factor are mitogens for primary cultures of mammary epithelium. *Biochem. Biophys. Res. Commun.*, **204**, 1165–1169 (1994).

42) Ram, T. G., Venkateswaran, V., Oliver, S. A. and Hosick, H. A.  A transforming growth factor related to epidermal growth factor is expressed by fetal mouse salivary mesenchyme cells in culture. *Biochem. Biophys. Res. Commun.*, **175**, 37–43 (1991).

43) Yang, J., Richards, J., Bowman, P., Guzman, R., Enami, J., McCormick, K., Hamamoto, S., Pitelka, D. and Nandi, S.  Sustained growth and three-dimensional organization of primary mammary tumor epithelial cells embedded in collagen gels. *Proc. Natl. Acad. Sci. USA.*, **76**, 3401–3405 (1979).

44) Berdievsky, F., Alford, D., D’Souza, B. and Taylor-Papadimitriou, J.  Branching morphogenesis of human mammary epithelial cells in collagen gels. *J. Cell Sci.*, **107**, 3557–3566 (1994).

45) Soriano, J. V., Pepper, M. S., Nakamura, T., Orci, L. and Montesano, R.  Hepatocyte growth factor stimulates extensive development of branching duct-like structure by cloned mammary gland epithelial cells. *J. Cell Sci.*, **108**, 413–430 (1995).

46) Guzman, R. C., Osborn, R. C., Richards, J. E. and Nandi, S.  Effects of phorbol esters on normal and tumorous mouse mammary epithelial cells embedded in collagen gels. *J. Natl. Cancer Inst.*, **71**, 69–73 (1983).

47) Kawamura, K., Enami, J. and Koga, M.  Stimulation of morphological changes and growth of mouse mammary tumor cells by 12-O-tetradecanoylphorbol-13-acetate (TPA). *J. Physiol. Soc. Jpn.*, **50**, 376 (1988).

48) Sastre, S., Sasaki, Y., Shiba, Y. and Kanno, Y.  Possible involvement of reorganization of actin filaments, induced by tumor-promoting phorbol esters, in changes in colony shape and enhancement of proliferation of cultured epithelial cells. *J. Cell Physiol.*, **132**, 49–56 (1987).

49) Enami, J., Kawamura, K., Kocezuka, M., Kawamura, K., Kusama, Y. and Koga, M.  Primary culture of epithelial cells in serum-free media. *Tissue Cult. Res. Commun.*, **7**, 96–98 (1998).

50) Dowrick, P. G., Prescott, A. R. and Warn, R. M.  Scatter factor affects major changes in the cytoskeletal organization of epithelial cells. *Cytokine*, **3**, 299–310 (1991).

51) Dugina, V. B., Alexandrova, A. Y., Lane, K., Bulanova, E. and Vasiliev, J. M.  The role of the microtubular system in the cell response to HGF/SF. *J. Cell Sci.*, **108**, 1659–1667 (1995).

52) Takaishi, K., Sasaki, T., Kato, M., Yamochi, W., Kuroda, S., Nakamura, T., Takeichi, M. and Takai, Y.  Involvement of Rho p21 small GTP-binding protein and its regulator in the HGF-induced cell motility. *Oncogene*, **9**, 273–279 (1994).

53) Nishiyama, T., Sasaki, T., Takaishi, K., Kato, M., Yaku, H., Araki, K., Matsura, Y. and Takai, Y.  *rac* p21 is involved in hepatocyte growth factor- and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced membrane ruffling in KB cells. *Mol. Cell. Biol.*, **14**, 2447–2456 (1994).

54) Seslar, S. P., Nakamura, T. and Byers, S. W.  Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide

---

Jpn. J. Cancer Res. **89**, November 1998

1142
growth factors. *Cancer Res.*, **53**, 1233–1238 (1993).

55) Weidner, K. M., Sachs, M. and Birchmeier, W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. *J. Cell Biol.*, **121**, 145–154 (1993).

56) Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D. and Wang, T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. *J. Clin. Invest.*, **97**, 2872–2877 (1996).

57) Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B. and Vande Woude, G. F. Activating mutations for the Met tyrosine kinase receptor in human cancer. *Proc. Natl. Acad. Sci. USA*, **94**, 11445–11450 (1997).

58) Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S. A. and Vande Woude, G. F. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. *Mol. Cell. Biol.*, **12**, 5152–5158 (1992).

59) Kanda, H., Tajima, H., Lee, G.-H., Nomura, K., Ohtake, K., Matsumoto, K., Nakamura, T. and Kitagawa, T. Hepatocyte growth factor transforms immortalized mouse liver epithelial cells. *Oncogene*, **8**, 3047–3053 (1993).

60) Bellusci, S., Moens, G., Gaudino, G., Comoglio, P., Nakamura, T., Thiery, J.-P. and Jouanneau, J. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. *Oncogene*, **9**, 1091–1099 (1994).

61) Rahimi, N., Tremblay, E., McAdam, L., Park, M., Schwall, R. and Elliott, B. Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. *Cell Growth Differ.*, **7**, 263–270 (1996).

62) Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M., Aaronson, S. A. and Merlino, G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. *Proc. Natl. Acad. Sci. USA*, **94**, 701–706 (1997).

63) Yang, Y., Spitzer, E., Meyer, D., Sachs, M., Niemann, C., Hartmann, G., Weidner, K. M., Birchmeier, C. and Birchmeier, W. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. *J. Cell Biol.*, **131**, 215–226 (1995).

64) Niranjan, B., Buluwela, L., Yant, J., Perusinghe, N., Atherton, A., Phippard, D., Dale, T., Gusterson, B. and Kamalati, T. HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. *Development*, **211**, 2897–2908 (1995).

65) Pepper, M. S., Soriano, J. V., Menoud, P. A., Sappino, A. P., Orci, L. and Montesano, R. Modulation of hepatocyte growth factor and c-met in the rat mammary gland during pregnancy, lactation, and involution. *Exp. Cell Res.*, **219**, 204–210 (1995).

66) Sakakura, T., Nishizuka, Y. and Dawe, C. J. Mesenchyme-dependent morphogenesis and epithelium-specific cypodifferentiation in mouse mammary gland. *Science*, **194**, 1439–1441 (1976).

67) Sakakura, T., Sakagami, Y. and Nishizuka, Y. Acceleration of mammary cancer development by grafting of fetal mammary mesenchymes in C3H mice. *Gann*, **70**, 459–466 (1979).